Neurobehavioral Disorders
Investigators report the findings from a study assessing the impact of insomnia on clinical outcomes in patients with major depressive disorder.
Neurobehavioral Disorders
Researchers examined the effect of neuropeptides orexin-A, ghrelin, and neuropeptide Y on hypersomnia and hyperphagia. Both symptoms are more common in people with bipolar disorder.
Neurobehavioral Disorders
Whether major depressive disorder is a comorbidity of bipolar disorder isn’t really known. Researchers built a predictive model of major depressive disorder to bipolar disorder conversion and with the Observational Medical Outcomes Partnership validated the results across a multi-national network of patient databases.
Neurobehavioral Disorders
Investigators assessed the safety and efficacy of lumateperone for the treatment of bipolar I and II disorders in patients experiencing major depressive episodes.
Neurobehavioral Disorders
The Company will evaluate BNC210 in patients with SAD in the phase 2 PREVAIL trial.
Neurobehavioral Disorders
Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.
Neurobehavioral Disorders
The researchers of this study explored the impact of a blended approach (bCBT) that included both face-to-face CBT and iCBT on patients with major depressive disorder and insomnia.
Neurobehavioral Disorders
Investigators conducted a systematic review of studies published between January 1, 2020 and January 29, 2021 that estimated the prevalence of major depressive disorder and anxiety disorders during the COVID-19 pandemic.
Neurobehavioral Disorders
Data for this study were sourced from 4 active treatment arms of 4 randomized, controlled trials conducted by the National Institutes of Health in the United States between 2006 and 2018.
General Neurology
This retrospective cohort study evaluated patient data from patients aged 50 years or older who received an acute course of ECT between 2011 and 2019 and were evaluated for cognition and depression outcomes on the basis of baseline cognitive function.